Abstract
Hepatitis C-associated liver disease is the most common indication for liver transplantation. Virological recurrence is ubiquitous. While the histological impact of recurrence varies substantially between recipients, approximately 30% of HCV-infected recipients will die or lose their allograft or develop cirrhosis secondary to hepatitis C recurrence by the fifth postoperative year. Viral, recipient, and donor factors affect the likelihood if more severe recurrence. Recipient and donor age, utilization of posttransplant antiviral therapy, higher pre- and posttransplant levels of HCV viremia, corticosteroid boluses for acute cellular rejection, Cytomegalovirus (CMV) disease, metabolic syndrome, HIV coinfection, and non-CC IL28B genotype all are associated with more severe recurrence. Strategies for minimizing the frequency of severe HCV recurrence are evolving and include avoidance of older donors, early diagnosis/treatment of CMV, and minimization of immunosuppression and avoidance of pulsed corticosteroid treatment of acute cellular rejection. Patients should be offered treatment with peginterferon and ribavirin as soon as histological evidence of recurrence of HCV is apparent.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000;32(5):1125–30.
Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41(5):830–6.
Futagawa Y, Terasaki PI, Waki K, et al. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant. 2006;6(6):1398–406.
Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110(1):167–77.
Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21(4):253–61.
Henry SD, Metselaar HJ, Van Dijck J, et al. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci. 2007;1110:439–47.
Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg. 1999;5(4 Suppl 1):S107–14.
Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl. 2002;8(10):884–8.
Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006;44(4):717–22.
Humar A, Crotteau S, Gruessner A, et al. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin Transplant. 2007;21(4):526–31.
Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol. 2007;47(6):793–8.
Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1- year interim results of the HCV-3 study. Liver Transpl. 2007;13(11):1521–31.
Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006;12(10):1464–72.
McAlister VC, Haddad E, Renouf E, et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006;6(7):1578–85.
Sugawara Y, Kaneko J, Makuuchi M. Cyclosporin a for treatment of hepatitis C virus after liver transplantation. Transplantation. 2006;82(4):579–80.
Firpi RJ, Soldevila-Pico C, Morelli GG, et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. Dig Dis Sci. 2010;55(1):196–203.
Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology. 2008;47(3):817–26.
Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology. 2006;131(5):1452–62.
Wiesner RH, Shorr JS, Steffen BJ, et al. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl. 2005;11(7):750–9.
Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl. 2001;7(11 Suppl 1):S60–73.
Lake J, Patel D, David K, et al. The association between MMF and risk of progressive renal dysfunction and death in adult liver transplant recipients with HCV. Clin Transplant. 2009;23(1):108–15.
Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004;78(7):966–71.
Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007;13(5):733–40.
Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl. 2009;15(11):1426–34.
Filipponi F, Salizzoni M, Grazi G, et al. Study of simulect-based, steroid-free immunosuppressive regimen in HCV + de novo liver transplant patients: preliminary results. Transplant Proc. 2001;33(7–8):3211–2.
Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–9.
Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126(3):840–8.
Leclercq IA, Da Silva Morais A, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47(1):142–56.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214–23.
Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006;68:123–58.
Saito K, Inoue S, Saito T, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut. 2002;51(1):100–4.
Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31.
Foufelle F, Ferre P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366(Pt 2):377–91.
Lawler Jr JF, Yin M, Diehl AM, et al. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J Biol Chem. 1998;273(9):5053–9.
Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24(9):1349–57.
Chen T, Jia H, Li J, et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int. 2009;22(4):408–15.
Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology. 2000;32(1):87–90.
Zein NN, Abdulkarim AS, Wiesner RH, et al. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32(2):209–17.
Kuo HT, Sampaio MS, Ye X, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation. 2010;89(9):1134–40.
Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6(8):1922–9.
Hoffmann CJ, Subramanian AK, Cameron AM, et al. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.
Steinmuller TH, Stockmann M, Bechstein WO, et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes. 2000;108(6):401–5.
Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72(6):1066–72.
Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation. 1997;64(5):721–6.
Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9(11):S1–9.
Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl. 2002;8(4):362–9.
Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant. 2002;2(5):461–6.
Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant. 2002;16(2):92–6.
Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002;35(8):974–81.
Miro JM, Montejo M, Rufi G, et al. Liver transplantation in patients with HIV infection: a reality in 2004. Enferm Infect Microbiol Clin. 2004;22(9):529–38.
Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371–86.
Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47(2):407–17.
Rifai K, Wedemeyer H, Rosenau J, et al. Longer survival of liver transplant recipients with hepatitis virus coinfections. Clin Transplant. 2007;21(2):258–64.
Taniguchi M, Shakil AO, Vargas HE, et al. Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: effect of viral hepatitis D. Liver Transpl. 2000;6(1):92–6.
Lai J, Verna E, Brown R, et al. Hepatitis C virus (HCV) infected females are at higher risk of graft loss after liver transplantation (LT): a multicenter cohort study. Hepatology. 2009;50:S304A–5.
Rustgi VK, Marino G, Halpern MT, et al. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl. 2002;8(6):514–8.
Knechtle SJ, Kalayolu M, D’Alessandro AM, et al. Histocompatibility and liver transplantation. Surgery 1993;114(4):667–71; discussion 671–2.
Kasahara M, Kiuchi T, Uryuhara K, et al. Role of HLA compatibility in pediatric living-related liver transplantation. Transplantation. 2002;74(8):1175–80.
Pyrsopoulos N, Jeffers L. Hepatitis C in African Americans. J Clin Gastroenterol. 2007;41(2):185–93.
Brady CW, Smith AD, Stechuchak KM, et al. Frequency and predictors of de novo hepatocellular carcinoma in patients awaiting orthotopic liver transplantation during the model for end-stage liver disease era. Liver Transpl. 2008;14(2):228–34.
Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology. 1998;28(3):823–30.
Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139:1586–92.
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9e18.
Burra P, Loreno M, Russo FP, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15(6):619–28.
Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003;9(5):500–5.
Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol. 2006;45(4):494–9.
Briceno J, Ciria R, Pleguezuelo M, et al. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc. 2007;39(7):2297–9.
Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl. 2000;6(4):407–12.
Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv + and HCV- recipients. Transplantation. 2004;77(12):1834–42.
Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002;236(3):315-22; discussion 322–3.
Watt KD, Lyden ER, Gulizia JM, et al. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl. 2006;12(1):134–9.
Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl. 2004;10(10):1248–55.
Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: a 6-year single center experience. Am J Transplant. 2005;5(1):149–56.
Pang PS, Kamal A, Glenn JS. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transpl. 2009;15(9):1126–32.
Ross W, Solomon H, Reese J, et al. Beneficial effects of HLA-DR3 gene expression on renal allograft survival in black recipients. Transplant Proc. 1993;25(4):2408–10.
Gjertson DW. Determinants of long-term survival of adult kidney transplants: a UNOS update. Clin Transpl. 1999;1999:341–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Veldt, B.J., Charlton, M.R. (2012). Natural History of Chronic HCV After Liver Transplantation. In: Shiffman, M. (eds) Chronic Hepatitis C Virus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1192-5_22
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1192-5_22
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1191-8
Online ISBN: 978-1-4614-1192-5
eBook Packages: MedicineMedicine (R0)